Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
- PMID: 16697652
- DOI: 10.1016/j.nbd.2006.02.011
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice
Abstract
The brain levels of the endogenous excitotoxin quinolinic acid (QUIN) and its bioprecursor, the free radical generator 3-hydroxykynurenine (3-HK), are elevated in early stage Huntington disease (HD). We now examined the status of these metabolites in three mouse models of HD. In R6/2 mice, 3-HK levels were significantly and selectively elevated in the striatum, cortex and cerebellum starting at 4 weeks of age. In contrast, both 3-HK and QUIN levels were increased in the striatum and cortex of the full-length HD models, beginning at 8 months (YAC128) and 15 months (Hdh(Q92) and Hdh(Q111)), respectively. No changes were seen in 13-month-old shortstop mice, which show no signs of motor or cognitive dysfunction or selective neuropathology. These results demonstrate both important parallels and intriguing differences in the progressive neurochemical changes in these HD mouse models and support the hypothesis that QUIN may play a role in the striatal and cortical neurodegeneration of HD.
Similar articles
-
Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease.Neurobiol Dis. 2004 Dec;17(3):455-61. doi: 10.1016/j.nbd.2004.07.006. Neurobiol Dis. 2004. PMID: 15571981
-
Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.Exp Neurol. 2006 Jan;197(1):31-40. doi: 10.1016/j.expneurol.2005.07.004. Epub 2005 Aug 15. Exp Neurol. 2006. PMID: 16099455
-
3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease?Adv Exp Med Biol. 2003;527:137-45. doi: 10.1007/978-1-4615-0135-0_16. Adv Exp Med Biol. 2003. PMID: 15206726
-
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.J Neurol Sci. 2012 Dec 15;323(1-2):1-8. doi: 10.1016/j.jns.2012.08.005. Epub 2012 Aug 29. J Neurol Sci. 2012. PMID: 22939820 Review.
-
Tryptophan metabolites and brain disorders.Clin Chem Lab Med. 2003 Jul;41(7):852-9. doi: 10.1515/CCLM.2003.129. Clin Chem Lab Med. 2003. PMID: 12940508 Review.
Cited by
-
Involvement of kynurenines in Huntington's disease and stroke-induced brain damage.J Neural Transm (Vienna). 2012 Feb;119(2):261-74. doi: 10.1007/s00702-011-0676-8. Epub 2011 Jun 22. J Neural Transm (Vienna). 2012. PMID: 21695417 Review.
-
Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities.Pharmacol Rev. 2024 Oct 16;76(6):978-1008. doi: 10.1124/pharmrev.124.000239. Pharmacol Rev. 2024. PMID: 39304346 Free PMC article. Review.
-
The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease.J Mol Med (Berl). 2013 Jun;91(6):705-13. doi: 10.1007/s00109-013-1046-9. Epub 2013 May 1. J Mol Med (Berl). 2013. PMID: 23636512 Review.
-
Does kynurenic acid act on nicotinic receptors? An assessment of the evidence.J Neurochem. 2020 Mar;152(6):627-649. doi: 10.1111/jnc.14907. Epub 2019 Nov 24. J Neurochem. 2020. PMID: 31693759 Free PMC article. Review.
-
5-Hydroxyanthranilic acid, a tryptophan metabolite, generates oxidative stress and neuronal death via p38 activation in cultured cerebellar granule neurones.Neurotox Res. 2009 May;15(4):303-10. doi: 10.1007/s12640-009-9034-0. Epub 2009 Mar 4. Neurotox Res. 2009. PMID: 19384564
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases